The funding round was led by AIX Ventures, with notable participation from investors such as Thiel Bio and Founders Fund.

The funds will support the launch of Ataraxis Breast, the world's first AI-native prognostic and predictive platform for breast cancer, clinically validated for its superior accuracy.

Co-founder Jan Witowski announced that the company plans to launch its first commercial test for breast cancer in the U.S. in the coming months.

Beyond breast cancer, Ataraxis aims to expand its offerings and develop next-generation AI models with the new funding.

This investment reflects a growing interest in AI applications within the healthcare sector, particularly in cancer diagnosis and treatment.

The foundation model, Kestrel, developed by Ataraxis, is noted for uncovering complex patterns in patient outcomes using less data and computational power than existing models.

Ataraxis AI, a New York-based startup, has successfully raised $20.4 million to personalize cancer treatment by predicting outcomes and potentially avoiding chemotherapy.

The startup aspires to impact at least half of new cancer cases by 2030, positioning itself as an innovative leader in healthcare AI, with guidance from Meta's chief AI scientist, Yann LeCun.

Ataraxis's AI technology analyzes high-resolution images of cancer cells and has demonstrated a 30% increase in accuracy over standard care in breast cancer detection.

The AI-driven cancer care sector is witnessing significant investment, with other companies like Valar Labs and Manas AI also raising substantial funds recently.

Ataraxis AI, founded by Jan Witowski and Krzysztof Geras, aims to transform cancer diagnostics and treatment through advanced AI technologies.

Ataraxis's Clinical Advisory Board includes prominent oncology figures such as Dr. Francisco Esteva and Dr. Lajos Pusztai, enhancing the company's credibility.